Foghorn Therapeutics Presents New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And For Selective CBP, EP300 And ARID1B Degrader Programs

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models

- Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer

- Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy

- Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability